Axel Dalhoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Axel Dalhoff has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
S. Schubert
University Hospital Kiel, Institute for Infection Medicine, Kiel, Germany
4 shared publicationsSabine Schubert
Christian-Albrechts University of Kiel, Kiel, Germany
3 shared publications- Andrej Weintraub
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
2 shared publications U. Ullmann
University Hospital Schleswig-Holstein, Campus Kiel
2 shared publicationsA. Rosowsky
1 shared publicationA. Vente
MerLion Pharmaceuticals, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 23 December 2020
- Published by Springer Nature in Infection
- Vol. 49 (1) , 29-56
Selective toxicity of antibacterial agents—still a valid concept or do we miss chances and ignore risks?
Background: Selective toxicity antibacteribiotics is considered to be due to interactions with targets either being unique to bacteria or being characterized by a dichotomy between pro- and eukaryotic pathways with high affinities of agents to bacterial- rather than eukaryotic targets. However, the theory of selective toxicity oversimplifies the complex modes of action of antibiotics in pro- and eukaryotes.Methods and objective: This review summarizes data describing multiple modes of action of antibiotics in eukaryotes.Results: Aminoglycosides, macrolides, oxazolidinones, chloramphenicol, clindamycin, tetracyclines, glycylcyclines, fluoroquinolones, rifampicin, bedaquillin, ß-lactams inhibited mitochondrial translation either due to binding to mitosomes, inhibition of mitochondrial RNA-polymerase-, topoisomerase 2ß-, ATP-synthesis, transporter activities. Oxazolidinones, tetracyclines, vancomycin, ß-lactams, bacitracin, isoniazid, nitroxoline inhibited matrix-metalloproteinases (MMP) due to chelation with zinc and calcium, whereas fluoroquinols fluoroquinolones and chloramphenicol chelated with these cations, too, but increased MMP activities. MMP-inhibition supported clinical efficacies of ß-lactams and daptomycin in skin-infections, and of macrolides, tetracyclines in respiratory-diseases. Chelation may have contributed to neuroprotection by ß-lactams and fluoroquinolones. Aminoglycosides, macrolides, chloramphenicol, oxazolidins oxazolidinones, tetracyclines caused read-through of premature stop codons. Several additional targets for antibiotics in human cells have been identified like interaction of fluoroquinolones with DNA damage repair in eukaryotes, or inhibition of mucin overproduction by oxazolidinones.Conclusion: The effects of antibiotics on eukaryotes are due to identical mechanisms as their antibacterial activities because of structural and functional homologies of pro- and eukaryotic targets, so that the effects of antibiotics on mammals are integral parts of their overall mechanisms of action.
- 23 December 2020
- Published by Springer Nature in Infection
- Vol. 49 (1) , 29-56
Open AccessSelective toxicity of antibacterial agents—still a valid concept or do we miss chances and ignore risks?
Background: Selective toxicity antibacteribiotics is considered to be due to interactions with targets either being unique to bacteria or being characterized by a dichotomy between pro- and eukaryotic pathways with high affinities of agents to bacterial- rather than eukaryotic targets. However, the theory of selective toxicity oversimplifies the complex modes of action of antibiotics in pro- and eukaryotes.Methods and objective: This review summarizes data describing multiple modes of action of antibiotics in eukaryotes.Results: Aminoglycosides, macrolides, oxazolidinones, chloramphenicol, clindamycin, tetracyclines, glycylcyclines, fluoroquinolones, rifampicin, bedaquillin, ß-lactams inhibited mitochondrial translation either due to binding to mitosomes, inhibition of mitochondrial RNA-polymerase-, topoisomerase 2ß-, ATP-synthesis, transporter activities. Oxazolidinones, tetracyclines, vancomycin, ß-lactams, bacitracin, isoniazid, nitroxoline inhibited matrix-metalloproteinases (MMP) due to chelation with zinc and calcium, whereas fluoroquinols fluoroquinolones and chloramphenicol chelated with these cations, too, but increased MMP activities. MMP-inhibition supported clinical efficacies of ß-lactams and daptomycin in skin-infections, and of macrolides, tetracyclines in respiratory-diseases. Chelation may have contributed to neuroprotection by ß-lactams and fluoroquinolones. Aminoglycosides, macrolides, chloramphenicol, oxazolidins oxazolidinones, tetracyclines caused read-through of premature stop codons. Several additional targets for antibiotics in human cells have been identified like interaction of fluoroquinolones with DNA damage repair in eukaryotes, or inhibition of mucin overproduction by oxazolidinones.Conclusion: The effects of antibiotics on eukaryotes are due to identical mechanisms as their antibacterial activities because of structural and functional homologies of pro- and eukaryotic targets, so that the effects of antibiotics on mammals are integral parts of their overall mechanisms of action.
- Open Access
- 15 December 2020
- Published by Springer Nature in Infection
- Vol. 49 (4) , 569-589
Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?
Purpose: Advances in structural biology, genetics, bioinformatics, etc. resulted in the availability of an enormous pool of information enabling the analysis of the ancestry of pro- and eukaryotic genes and proteins. Methods: This review summarizes findings of structural and/or functional homologies of pro- and eukaryotic enzymes catalysing analogous biological reactions because of their highly conserved active centres so that non-antibiotics interacted with bacterial targets. Results: Protease inhibitors such as staurosporine or camostat inhibited bacterial serine/threonine or serine/tyrosine protein kinases, serine/threonine phosphatases, and serine/threonine kinases, to which penicillin-binding-proteins are linked, so that these drugs synergized with β-lactams, reverted aminoglycoside-resistance and attenuated bacterial virulence. Calcium antagonists such as nitrendipine or verapamil blocked not only prokaryotic ion channels but interacted with negatively charged bacterial cell membranes thus disrupting membrane energetics and inducing membrane stress response resulting in inhibition of P-glycoprotein such as bacterial pumps thus improving anti-mycobacterial activities of rifampicin, tetracycline, fluoroquinolones, bedaquilin and imipenem-activity against Acinetobacter spp. Ciclosporine and tacrolimus attenuated bacterial virulence. ACE-inhibitors like captopril interacted with metallo-β-lactamases thus reverting carbapenem-resistance; prokaryotic carbonic anhydrases were inhibited as well resulting in growth impairment. In general, non-antibiotics exerted weak antibacterial activities on their own but synergized with antibiotics, and/or reverted resistance and/or attenuated virulence. Conclusions: Data summarized in this review support the theory that prokaryotic proteins represent targets for non-antibiotics because of a common evolutionary origin of bacterial- and mammalian targets resulting in highly conserved active centres of both, pro- and eukaryotic proteins with which the non-antibiotics interact and exert antibacterial actions.
- 15 December 2020
- Published by Springer Nature in Infection
- Vol. 49 (4) , 569-589
Open AccessAre antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?
Purpose: Advances in structural biology, genetics, bioinformatics, etc. resulted in the availability of an enormous pool of information enabling the analysis of the ancestry of pro- and eukaryotic genes and proteins. Methods: This review summarizes findings of structural and/or functional homologies of pro- and eukaryotic enzymes catalysing analogous biological reactions because of their highly conserved active centres so that non-antibiotics interacted with bacterial targets. Results: Protease inhibitors such as staurosporine or camostat inhibited bacterial serine/threonine or serine/tyrosine protein kinases, serine/threonine phosphatases, and serine/threonine kinases, to which penicillin-binding-proteins are linked, so that these drugs synergized with β-lactams, reverted aminoglycoside-resistance and attenuated bacterial virulence. Calcium antagonists such as nitrendipine or verapamil blocked not only prokaryotic ion channels but interacted with negatively charged bacterial cell membranes thus disrupting membrane energetics and inducing membrane stress response resulting in inhibition of P-glycoprotein such as bacterial pumps thus improving anti-mycobacterial activities of rifampicin, tetracycline, fluoroquinolones, bedaquilin and imipenem-activity against Acinetobacter spp. Ciclosporine and tacrolimus attenuated bacterial virulence. ACE-inhibitors like captopril interacted with metallo-β-lactamases thus reverting carbapenem-resistance; prokaryotic carbonic anhydrases were inhibited as well resulting in growth impairment. In general, non-antibiotics exerted weak antibacterial activities on their own but synergized with antibiotics, and/or reverted resistance and/or attenuated virulence. Conclusions: Data summarized in this review support the theory that prokaryotic proteins represent targets for non-antibiotics because of a common evolutionary origin of bacterial- and mammalian targets resulting in highly conserved active centres of both, pro- and eukaryotic proteins with which the non-antibiotics interact and exert antibacterial actions.
- 1 June 2018
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 13, 40-48
Does the use of antifungal agents in agriculture and food foster polyene resistance development? A reason for concern
- 1 June 2018
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 13, 40-48
Does the use of antifungal agents in agriculture and food foster polyene resistance development? A reason for concern
- 1 February 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (2)
Seventy-Five Years of Research on Protein Binding
This review summarizes evidence that the impact of protein binding of the activity of antibiotics is multifaceted and more complex than indicated by the numerical value of protein binding alone. A plethora of studies has proven that protein binding of antibiotics matters, as the free fraction only is antibacterially active and governs pharmacokinetics. Several studies have indicated that independent from protein binding of immunoglobulin G, albumin, α1-acid-glycoprotein, and pulmonary surfactant acted synergistically with antibacterial agents, thus suggesting that some intrinsic properties of serum proteins may have mediated serum-antibiotic synergisms. It has been demonstrated that IgG and albumin permeabilized Gram-negative and Gram-positive bacteria and facilitated the uptake of poorly penetrating antibiotics. Alpha-1-acid-glycoprotein and pulmonary surfactant also exerted a permeabilizing activity, but proof that this property results in a sensitizing effect is missing. The permeabilizing effect of serum proteins may explain why serum-antibiotic synergisms do not represent a general phenomenon but are limited to specific drug-bug associations only. Although evidence has been generated to support the hypothesis that native serum proteins interact synergistically with antibiotics, systematic and well-controlled studies have to be performed to substantiate this phenomenon. The interactions between serum proteins and bacterial surfaces are driven by physicochemical forces. However, preparative techniques, storage conditions, and incubation methods have a significant impact on the intrinsic activities of these serum proteins affecting serum-antibiotic synergisms, so these techniques have to be standardized; otherwise, contradictory data or even artifacts will be generated.
- 1 February 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (2)
Seventy-Five Years of Research on Protein Binding
This review summarizes evidence that the impact of protein binding of the activity of antibiotics is multifaceted and more complex than indicated by the numerical value of protein binding alone. A plethora of studies has proven that protein binding of antibiotics matters, as the free fraction only is antibacterially active and governs pharmacokinetics. Several studies have indicated that independent from protein binding of immunoglobulin G, albumin, α1-acid-glycoprotein, and pulmonary surfactant acted synergistically with antibacterial agents, thus suggesting that some intrinsic properties of serum proteins may have mediated serum-antibiotic synergisms. It has been demonstrated that IgG and albumin permeabilized Gram-negative and Gram-positive bacteria and facilitated the uptake of poorly penetrating antibiotics. Alpha-1-acid-glycoprotein and pulmonary surfactant also exerted a permeabilizing activity, but proof that this property results in a sensitizing effect is missing. The permeabilizing effect of serum proteins may explain why serum-antibiotic synergisms do not represent a general phenomenon but are limited to specific drug-bug associations only. Although evidence has been generated to support the hypothesis that native serum proteins interact synergistically with antibiotics, systematic and well-controlled studies have to be performed to substantiate this phenomenon. The interactions between serum proteins and bacterial surfaces are driven by physicochemical forces. However, preparative techniques, storage conditions, and incubation methods have a significant impact on the intrinsic activities of these serum proteins affecting serum-antibiotic synergisms, so these techniques have to be standardized; otherwise, contradictory data or even artifacts will be generated.
- 29 November 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (04) , 435-446
Neue Antibiotika in der Forschung – Teil 3: β-Laktame und β-Laktamase-Inhibitoren
Im Wettlauf mit den zunehmenden Resistenzraten wird fieberhaft an der Entwicklung neuer Antibiotika gearbeitet. Welches Potenzial und antibakterielle Spektrum die β-Laktame und β-Laktamase-Inhibitoren gegenüber gramnegativen ESCAPE-Pathogenen haben, lesen Sie im 3. Teil dieser Beitragsreihe.
- 29 November 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (04) , 435-446
Neue Antibiotika in der Forschung – Teil 3: β-Laktame und β-Laktamase-Inhibitoren
Im Wettlauf mit den zunehmenden Resistenzraten wird fieberhaft an der Entwicklung neuer Antibiotika gearbeitet. Welches Potenzial und antibakterielle Spektrum die β-Laktame und β-Laktamase-Inhibitoren gegenüber gramnegativen ESCAPE-Pathogenen haben, lesen Sie im 3. Teil dieser Beitragsreihe.
- 12 September 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (03) , 299-314
Neue Antibiotika in der Forschung – Teil 2: Proteinsyntheseinhibitoren
Die zunehmenden Resistenzen gramnegativer Bakterien sind in den letzten Jahren weltweit zu einer ernsthaften Bedrohung geworden. Daher ist es von großer Bedeutung, ein besonderes Augenmerk auf die Entwicklung antibakteriell wirksamer Substanzen zu richten, die auch das gramnegative Erregerspektrum abdecken. Nicht weniger bedeutsam ist das Entwickeln von Wirkstoffen, die gegen resistente Pathogene aktiv sind. Dieser 2. Teil der Reihe über neue Antibiotika geht auf die Entwicklungspräparate aus dem Bereich der Proteinsyntheseinhibitoren und deren In-vitro-Aktivität ein.
- 12 September 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (03) , 299-314
Neue Antibiotika in der Forschung – Teil 2: Proteinsyntheseinhibitoren
Die zunehmenden Resistenzen gramnegativer Bakterien sind in den letzten Jahren weltweit zu einer ernsthaften Bedrohung geworden. Daher ist es von großer Bedeutung, ein besonderes Augenmerk auf die Entwicklung antibakteriell wirksamer Substanzen zu richten, die auch das gramnegative Erregerspektrum abdecken. Nicht weniger bedeutsam ist das Entwickeln von Wirkstoffen, die gegen resistente Pathogene aktiv sind. Dieser 2. Teil der Reihe über neue Antibiotika geht auf die Entwicklungspräparate aus dem Bereich der Proteinsyntheseinhibitoren und deren In-vitro-Aktivität ein.
- 12 June 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (02) , 179-193
Neue Antibiotika in der Forschung – Teil 1: Chinolone und Gepotidacin
Im Angesicht zunehmender Resistenzraten kommt der Entwicklung von neuen Antibiotika eine fundamentale Bedeutung zu. Die In-vitro-Aktivität der neuen Substanzen gegenüber ESCAPE-Bakterien verdient besondere Beachtung; in diesem Beitrag stehen speziell die Topoisomerase-Inhibitoren Chinolon und Gepotidacin und die antibakterielle Aktivität der einzelnen klinischen Entwicklungskandidaten gegenüber sog. „Problemkeimen“ im Fokus.
- 12 June 2017
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 12 (02) , 179-193
Neue Antibiotika in der Forschung – Teil 1: Chinolone und Gepotidacin
Im Angesicht zunehmender Resistenzraten kommt der Entwicklung von neuen Antibiotika eine fundamentale Bedeutung zu. Die In-vitro-Aktivität der neuen Substanzen gegenüber ESCAPE-Bakterien verdient besondere Beachtung; in diesem Beitrag stehen speziell die Topoisomerase-Inhibitoren Chinolon und Gepotidacin und die antibakterielle Aktivität der einzelnen klinischen Entwicklungskandidaten gegenüber sog. „Problemkeimen“ im Fokus.
- Open Access
- 1 May 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (5)
Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
The pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae isolates were compared. Since quinolones lose activity in acidic media, and particularly in urine, their activities were tested in parallel under conventional conditions and in acidic artificial urine. For this purpose, TEM- and SHV-type ESBL-producing Escherichia coli and Klebsiella pneumoniae strains and their wild-type counterparts were exposed in a modified Grasso model to simulated concentrations of drugs in serum and urine following oral doses of either finafloxacin at 800 mg once a day (q.d.), immediate-release ciprofloxacin at 500 mg twice a day (b.i.d.), extended-release ciprofloxacin at 1,000 mg q.d., or levofloxacin at 500 or 750 mg q.d. The concentrations of the drugs in urine were fitted by compartmental modeling. Bacteria were cultivated in Mueller-Hinton broth (MHB) at pH 7.2 or 5.8 or in artificial urine at pH 5.8. Bacteria were counted every 2 h until 10 h and at 24 h; the areas under the bacterial-count–versus–time curves were calculated. It was found that finafloxacin eliminated all strains within 2 h under all the conditions studied. At all doses studied, ciprofloxacin and levofloxacin were highly active against wild-type strains in MHB at pH 7.2 but lost activity in MHB, and particularly in urine, at pH 5.8. Viable counts of ESBL producers were reduced for 6 to 8 h by 3 log 10 titers, but the bacteria regrew thereafter. Ciprofloxacin and levofloxacin were almost inactive against the SHV producer grown in artificial urine. We conclude that pharmacodynamic models using artificial urine may mirror the physiology of urinary tract infections more closely than those using conventional media. In contrast to ciprofloxacin and levofloxacin, finafloxacin gained activity in this model at an acidic pH, maintained activity in artificial urine, and was active against TEM and SHV producers.
- 1 May 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (5)
Open AccessPharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
The pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae isolates were compared. Since quinolones lose activity in acidic media, and particularly in urine, their activities were tested in parallel under conventional conditions and in acidic artificial urine. For this purpose, TEM- and SHV-type ESBL-producing Escherichia coli and Klebsiella pneumoniae strains and their wild-type counterparts were exposed in a modified Grasso model to simulated concentrations of drugs in serum and urine following oral doses of either finafloxacin at 800 mg once a day (q.d.), immediate-release ciprofloxacin at 500 mg twice a day (b.i.d.), extended-release ciprofloxacin at 1,000 mg q.d., or levofloxacin at 500 or 750 mg q.d. The concentrations of the drugs in urine were fitted by compartmental modeling. Bacteria were cultivated in Mueller-Hinton broth (MHB) at pH 7.2 or 5.8 or in artificial urine at pH 5.8. Bacteria were counted every 2 h until 10 h and at 24 h; the areas under the bacterial-count–versus–time curves were calculated. It was found that finafloxacin eliminated all strains within 2 h under all the conditions studied. At all doses studied, ciprofloxacin and levofloxacin were highly active against wild-type strains in MHB at pH 7.2 but lost activity in MHB, and particularly in urine, at pH 5.8. Viable counts of ESBL producers were reduced for 6 to 8 h by 3 log 10 titers, but the bacteria regrew thereafter. Ciprofloxacin and levofloxacin were almost inactive against the SHV producer grown in artificial urine. We conclude that pharmacodynamic models using artificial urine may mirror the physiology of urinary tract infections more closely than those using conventional media. In contrast to ciprofloxacin and levofloxacin, finafloxacin gained activity in this model at an acidic pH, maintained activity in artificial urine, and was active against TEM and SHV producers.